Pfizer ready for post-COVID sales

Pfizer recently cut its outlook for 2023 due to declining demand for its COVID-19 vaccines and treatments. However, the company is using the huge profits it earned on those products to buy other drugmakers with promising products.
We feel these moves, as well as Pfizer’s own… Read More

High debt loads hold them back

In the past few years, big pharmaceutical companies have spun off their consumer drug operations. That’s part of their strategy to focus on more-profitable prescription drug businesses. These two recent spinoffs have decent long-term prospects, but their shares will likely remain depressed until they cut… Read More